Johnson & Johnson (NYSE:JNJ) Shares Sold by BLB&B Advisors LLC

BLB&B Advisors LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.4% in the third quarter, HoldingsChannel.com reports. The fund owned 75,431 shares of the company’s stock after selling 11,645 shares during the quarter. BLB&B Advisors LLC’s holdings in Johnson & Johnson were worth $12,224,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Tempus Wealth Planning LLC boosted its stake in shares of Johnson & Johnson by 3.9% during the third quarter. Tempus Wealth Planning LLC now owns 8,808 shares of the company’s stock valued at $1,427,000 after acquiring an additional 328 shares during the last quarter. Pictet North America Advisors SA boosted its stake in shares of Johnson & Johnson by 21.0% during the 3rd quarter. Pictet North America Advisors SA now owns 4,295 shares of the company’s stock worth $696,000 after purchasing an additional 745 shares during the last quarter. Symphony Financial Ltd. Co. grew its holdings in shares of Johnson & Johnson by 5.2% during the third quarter. Symphony Financial Ltd. Co. now owns 37,358 shares of the company’s stock worth $6,029,000 after buying an additional 1,834 shares in the last quarter. Waldron Private Wealth LLC raised its position in shares of Johnson & Johnson by 4.5% in the third quarter. Waldron Private Wealth LLC now owns 40,560 shares of the company’s stock valued at $6,573,000 after buying an additional 1,761 shares during the last quarter. Finally, WT Wealth Management purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $211,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on JNJ. Royal Bank of Canada boosted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. TD Cowen reduced their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Citigroup upped their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $165.86 on Thursday. The company has a market capitalization of $399.17 billion, a PE ratio of 10.34, a P/E/G ratio of 2.65 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average is $163.29 and its two-hundred day moving average is $154.92. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.66 earnings per share. Analysts predict that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 2.99%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.